1xbet 보너스 코드., Ltd.
Bristol-Myers K.K.
Pharmaceuticals
March 2, 2015
1xbet 보너스 코드
1xbet 보너스 코드., Ltd. and the U.S.-based company Bristol-Myers Squibb have agreed to end the co-promotion arrangements for the drug SPRYCEL®(generic name: dasatinib) 1xbet 보너스 코드, effective from February 27, 2015.
1xbet 보너스 코드 established a global contract in April 2009 in the area of hematological cancers and have been co-promoting SPRYCEL®for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia 1xbet 보너스 코드 since January 2011. Bristol-Myers K.K. continues to promote SPRYCEL®1xbet 보너스 코드
1xbet 보너스 코드 will continue to receive a specified collaboration fee for SPRYCEL net sales in the U.S., Europe*, and Japan. There will be no decrease or other change in terms for the collaboration fee 1xbet 보너스 코드 receives as a result of the termination of co-promotion in Japan.
This change to the agreement is specific to Japan and independent of Bristol-Myers Squibb's partnership with 1xbet 보너스 코드 in the U.S. and Europe.
- Europe: 5 countries consist1xbet 보너스 코드g of France, Germany, Italy, Spa1xbet 보너스 코드 and the U.K.
Latest Pharmaceutical Bus1xbet 보너스 코드ess related News Releases